In this podcast (11:01 minutes), we’ll be exploring some of the most groundbreaking findings from the 2024 European Society for Medical Oncology (ESMO) Congress, which took place in Barcelona, Spain, 12-17 September. We’ve seen tremendous strides in oncology this year, with new data emerging from several critical clinical trials. This podcast highlights 6 key studies that are not only reshaping current treatment paradigms but are also offering new hope for patients worldwide:
- Both NICHE-2 and NICHE-3 trials show high efficiency of short neoadjuvant immunotherapy in dMMR colon cancer
- Neoadjuvant nivolumab/ipilimumab improves DMFS in stage III resectable melanoma
- Trastuzumab deruxtecan also effective in patients with brain metastases
- Adding lenvatinib plus pembrolizumab to TACE improves survival in intermediate-stage hepatocellular cancer
- Doublet maintenance therapy does not outperform monotherapy in ovarian cancer
- Increased OS with pembrolizumab in newly diagnosed, high-risk, locally advanced cervical cancer
Enjoy listening!
Posted on
Table of Contents: ESMO 2024
Featured articles
Meet the Trialist: Prof. Fred Saad shares insights from the ARANOTE trial
Gastrointestinal Cancer
Neoadjuvant chemoradiation does not improve surgical outcomes or survival in pancreatic cancer
Adding lenvatinib plus pembrolizumab to TACE improves PFS in intermediate-stage HCC
Benefit of adjuvant atezolizumab/bevacizumab in HCC not maintained over time
Pre-operative chemoradiation does not improve survival in resectable gastric cancer
Final results of the IKF-AIO-Moonlight trial
Gastrointestinal: Colorectal Cancer
Retifanlimab boosts survival in patients with anal cancer
NICHE-2 and NICHE-3 show high efficacy of short neoadjuvant immunotherapy in dMMR colon cancer
Organ-preserving regimens in rectal cancer
No benefit of high-dose vitamin D3 supplementation in mCRC
Breast Cancer
Trastuzumab deruxtecan also effective in patients with brain metastases
High pCR rates with dual neoadjuvant immunotherapy in TIL-high TNBC
Local HER2 IHC0 is often HER2-low or -ultralow
First-line capivasertib improves PFS but not OS in metastatic TNBC
Breastfeeding does not increase the risk of breast cancer recurrence
Lung Cancer
Adjuvant durvalumab does not improve survival in completely resected NSCLC
NVL-655: a promising new option in pre-treated, drug-resistant ALK-mutated NSCLC
Relatlimab addition benefits only a subgroup of metastatic NSCLC
Melanoma
Neoadjuvant nivolumab/ipilimumab improves DMFS in stage III resectable melanoma
New neoadjuvant combinations in stage III melanoma
Genitourinary Cancer
Rethinking immune rechallenge: Tivozanib monotherapy emerges as a promising post-ICI option in metastatic RCC
Perioperative durvalumab combined with neoadjuvant chemotherapy improves survival in bladder cancer
Watchful waiting is non-inferior to BCG in patients with T0 after second transurethral resection
Faecal transplants show promise in enhancing metastatic RCC treatment
Genitourinary: Prostate Cancer
Combination of radium-223 and enzalutamide benefits patients with mCRPC with bone metastases
177Lu-PSMA effective both in mCRPC and mHSPC
Decipher score is predictive for docetaxel-benefit in mestastatic prostate cancer
Final OS for CONTACT-02 trial in mCRPC
Gynaecological Cancer
Increased OS with pembrolizumab in newly diagnosed, high-risk, locally advanced cervical cancer
Doublet maintenance therapy does not outperform monotherapy in ovarian cancer
Benefit of pembrolizumab in dMMR, newly diagnosed, high-risk endometrial cancer
No OS benefit of niraparib maintenance in high-risk ovarian cancer
site created by:
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com